...
首页> 外文期刊>ACS Omega >The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
【24h】

The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration

机译:反复给药后药代动力学和毒代动力学研究表明补骨脂素的积累有助于其肝毒性。

获取原文

摘要

Psoralen is a furanocoumarin compound found in many herb medicines and is claimed to contribute to the hepatotoxicity caused by lots of traditional Chinese medicine. So far, there has been no research on the differences in pharmacokinetics of single and repeated dosing of psoralen. Moreover, the research on the cumulative toxicity of low concentration and long-term administration on cells has not been reported. Therefore, this study investigated the pharmacokinetic differences and the accumulated cytotoxicity of psoralen from repeated administration. The study found that after single or repeated administration of psoralen for 3 months at various dosages (14, 28, and 56 mg/kg), the pharmacokinetic parameters of female rats between single dose and repeated dose administration are totally different. Compared with a single administration, multiple administrations increased psoralen’s in vivo exposure, prolonged the peak time, prolonged the half-life of the drug, reduced the drug clearance rate, and prolonged the drug’s stay in the body. HepG2 cells were exposed to low doses (5, 10, 20, or 40 μM) of psoralen for 1, 2, 3, or 4 days. A 20 and 40 μM dose of psoralen did not induced cell death in the 1st day but significantly decreased the cell viability at the 3rd and 4th day of repeated administration, respectively. In addition, multiple administrations of psoralen decreased cell viability due to G2 arrest.
机译:补骨脂素是一种呋喃香豆素化合物,存在于许多草药中,据称会导致许多中药引起的肝毒性。迄今为止,尚未有关于补骨脂素单次和重复给药的药代动力学差异的研究。此外,关于低浓度和长期施用对细胞的累积毒性的研究尚未见报道。因此,本研究调查了反复服用补骨脂素的药代动力学差异和累积的细胞毒性。研究发现,以不同剂量(14、28和56 mg / kg)单次或重复补骨脂素给药3个月后,雌性大鼠在单剂量和重复给药之间的药代动力学参数完全不同。与单次给药相比,多次给药可增加补骨脂素的体内暴露量,延长峰值时间,延长药物的半衰期,降低药物清除率,并延长药物在体内的停留时间。将HepG2细胞暴露于低剂量(5、10、20或40μM)补骨脂素中1、2、3或4天。补骨脂素的20和40μM剂量在第1天未诱导细胞死亡,但在重复给药的第3天和第4天分别显着降低了细胞活力。另外,补骨脂素的多次施用由于G2停滞而降低了细胞活力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号